Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products to treat serious and life-threatening diseases. The company’s product pipeline includes two phase III product candidates. The first, Blisibimod, is currently being studied for the treatment of lupus, a chronic disease that causes a patient’s immune system to attack his or her own tissues and organs. The second, Sollpura™, is currently being studied as a novel pancreatic enzyme replacement therapy for the treatment of cystic fibrosis and related diseases.
In recent months, Anthera made major strides toward the eventual commercialization of these two groundbreaking drug candidates. In March, the company secured a research award of up to $3 million from Cystic Fibrosis Foundation Therapeutics, Inc. to support the manufacturing and clinical development of Sollpura.
“Support from Cystic Fibrosis Foundation Therapeutics speaks to the importance of developing [Sollpura] and the organization’s extensive clinical trials network will be indispensable as we advance this therapy,” Paul F. Truex, president and chief executive officer of Anthera, stated in a news release.
Earlier this month, the company made significant progress in the development of Blisibimod by reaching the target enrollment goal for its CHABLIS-SC1 phase III clinical trial. The results from this study, which are expected to be available in the second half of 2016, are anticipated to support the eventual market approval of Blisibimod for the treatment of lupus.
“Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” stated Dr. Colin Hislop, chief medical officer of Anthera. “The accelerated pace speaks to the importance of patient identification and selection in lupus treatment.”
When commercialized, these two products could provide Anthera with a strong platform to realize considerable growth within the biopharmaceutical industry. According to the Lupus Foundation of America, an estimated 1.5 million Americans, and at least five million people worldwide, suffer from some form of Lupus. Likewise, according to the Cystic Fibrosis Foundation, an estimated 30,000 Americans, and approximately 70,000 people worldwide, suffer from cystic fibrosis.
For prospective investors, Anthera’s continued progress toward commercialization of its two unique drug candidates makes the company an intriguing investment opportunity in the months to come.
For more information, visit www.anthera.com